Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics (ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The options allow purchase of 16,500 shares at an exercise price of $7.43 per share, matching the closing price on February 3, 2025.
The options will vest over four years, with 25% vesting after the first year of employment and the remaining shares vesting monthly over the following 36 months. These grants comply with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees.
Astria Therapeutics (ATXS), un'azienda biofarmaceutica che sviluppa terapie per malattie allergiche e immunologiche, ha concesso opzioni su azioni a due nuovi dipendenti nell'ambito del suo Piano di Incentivazione Sulle Azioni per il 2022. Queste opzioni consentono l'acquisto di 16.500 azioni a un prezzo di esercizio di $7,43 per azione, corrispondente al prezzo di chiusura del 3 febbraio 2025.
Le opzioni matureranno nell'arco di quattro anni, con il 25% che matura dopo il primo anno di impiego e le azioni rimanenti che matureranno mensilmente nei successivi 36 mesi. Questi concessioni sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) per premi di incentivazione ai nuovi dipendenti.
Astria Therapeutics (ATXS), una empresa biofarmacéutica que desarrolla terapias para enfermedades alérgicas e inmunológicas, ha otorgado opciones sobre acciones a dos nuevos empleados bajo su Plan de Incentivo de Acciones por Inducción 2022. Las opciones permiten la compra de 16,500 acciones a un precio de ejercicio de $7.43 por acción, coincidiendo con el precio de cierre del 3 de febrero de 2025.
Las opciones se consolidarán en un periodo de cuatro años, con un 25% consolidándose después del primer año de empleo y las acciones restantes consolidándose mensualmente en los 36 meses siguientes. Estas concesiones cumplen con la Regla de Cotización Nasdaq 5635(c)(4) para premios de inducción a nuevos empleados.
Astria Therapeutics (ATXS)는 알레르기 및 면역 질환 치료제를 개발하는 생물 제약 회사로, 2022 유인 주식 인센티브 플랜에 따라 두 명의 신규 직원에게 주식 옵션을 부여했습니다. 이 옵션은 16,500주를 주당 $7.43의 행사가격으로 구매할 수 있으며, 이는 2025년 2월 3일의 종가와 일치합니다.
이 옵션은 4년에 걸쳐 발생하며, 25%는 첫 해의 근무 후 발생하고 나머지 주식은 다음 36개월 동안 매월 발생합니다. 이 보상은 신규 직원에 대한 유인 보상에 대한 나스닥 상장 규칙 5635(c)(4)를 준수합니다.
Astria Therapeutics (ATXS), une entreprise biopharmaceutique développant des thérapies pour les maladies allergiques et immunologiques, a accordé des options d'achat d'actions à deux nouveaux employés dans le cadre de son Plan d'Incentive d'Actions par Induction de 2022. Ces options permettent l'achat de 16.500 actions à un prix d'exercice de $7,43 par action, correspondant au prix de clôture du 3 février 2025.
Les options deviendront acquises sur une période de quatre ans, avec 25% des options acquises après la première année d'emploi et les actions restantes acquises mensuellement au cours des 36 mois suivants. Ces attributions respectent la règle de cotation Nasdaq 5635(c)(4) pour les récompenses d'incitation aux nouveaux employés.
Astria Therapeutics (ATXS), ein biopharmazeutisches Unternehmen, das Therapien für allergische und immunologische Erkrankungen entwickelt, hat Aktienoptionen an zwei neue Mitarbeiter im Rahmen seines 2022 Inducement Stock Incentive Plans gewährt. Die Optionen ermöglichen den Kauf von 16.500 Aktien zu einem Ausübungspreis von $7,43 pro Aktie, was dem Schlusskurs am 3. Februar 2025 entspricht.
Die Optionen werden über vier Jahre fällig, wobei 25% nach dem ersten Jahr der Anstellung fällig wird und die verbleibenden Aktien monatlich über die folgenden 36 Monate fällig werden. Diese Zuwendungen entsprechen der Nasdaq-Listing-Regel 5635(c)(4) für Anreizvergaben an neue Mitarbeiter.
- None.
- None.
The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204500671/en/
Astria Contact:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
What is the exercise price of ATXS stock options granted on February 3, 2025?
How many shares were included in ATXS's February 2025 inducement stock option grants?
What is the vesting schedule for ATXS's February 2025 inducement grants?
Under which plan were ATXS's February 2025 stock options granted?
